Anal Cancer – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Anal Cancer – Drugs In Development, 2023’, provides an overview of the Anal Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Anal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anal Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Anal Cancer
- The report reviews pipeline therapeutics for Anal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Anal Cancer therapeutics and enlists all their major and minor projects
- The report assesses Anal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Anal Cancer
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Anal Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Anal Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
Adagene Suzhou LtdAlligator Bioscience AB
Artios Pharma Ltd
Ascendis Pharma AS
AstraZeneca Plc
Beijing Corregene Biotechnology Co Ltd
Beijing Health Guard Biotechnology Inc
Bicara Therapeutics Inc
Biomimetix JV LLC
Bristol-Myers Squibb Co
Buzzard Pharmaceuticals AB
Cue Biopharma Inc
CytomX Therapeutics Inc
Eli Lilly and Co
EpimAb Biotherapeutics Inc
eTheRNA Immunotherapies NV
F. Hoffmann-La Roche Ltd
Fujifilm Holdings Corp
Gene Surgery
Genentech USA Inc
Gilead Sciences Inc
Guangzhou BeBetter Medicine Technology Co Ltd
Hengrui Yuanzheng Biotechnology Co Ltd
HotSpot Therapeutics Inc
IMV Inc
Incyte Corp
Invectys SA
Invion Ltd
ISA Pharmaceuticals BV
Johnson & Johnson
L&L Biopharma Co Ltd
Marengo Therapeutics Inc
Merck & Co Inc
Merck KGaA
Mereo Biopharma Group Plc
Merus NV
Molecular Partners AG
Nektar Therapeutics
Novartis AG
Nykode Therapeutics ASA
OncoC4 Inc
Oncolytics Biotech Inc
OSE Immunotherapeutics SA
PDS Biotechnology Corp
Precigen Inc
Privo Technologies Inc
Revolution Medicines Inc
Shanghai Bovax Biotechnology Co Ltd
Shanghai De Novo Pharmatech Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Zerun Biotechnology Co Ltd
SinoCelltech Group Ltd
SOTIO Biotech AS
SQZ Biotechnologies Co
Statera Biopharma Inc
Stcube Inc
Sumitomo Dainippon Pharma Oncology
Inc
Theravectys SA
Transcenta Holding Ltd
Transgene SA
Treadwell Therapeutics Inc
TScan Therapeutics Inc
University of Pittsburgh
Virion Therapeutics LLC
Voltron Therapeutics Inc
Xencor Inc
Y-Biologics Inc
Zai Lab Ltd
Zhejiang Pharmaceutical Co Ltd
Zymeworks Inc